GlassScriptPhysician profile
Louis Komer
NPI 1386662260
$5,461.65
in general payments reported to CMS, 2019-2025
35 companies · $889 in 2025
The $889 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,040 · 2020: $151 · 2021: $589 · 2022: $814 · 2023: $863 · 2024: $1,114 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,867.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,986.31 | 2021-2025 | |
| Novo Nordisk INC | $1,111.35 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $429.58 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $259.40 | 2019-2025 | |
| Lilly USA, LLC | $247.58 | 2019-2023 | Mounjaro |
| Amgen INC. | $210.21 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $135.64 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.75 | 2019-2024 | Jardiance, Synjardy |
| Allergan, INC. | $121.84 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $97.63 | 2019-2024 | Airsupra |
| Exact Sciences Corporation | $76.16 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $65.47 | 2019-2024 | |
| Inari Medical, INC. | $55.27 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $52.81 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $46.12 | 2019-2024 | Spravato |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $43.13 | 2020-2022 | |
| Astellas Pharma US INC | $40.73 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $37.90 | 2019 | |
| Lundbeck LLC | $32.53 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $29.16 | 2022 | |
| Avanir Pharmaceuticals, INC. | $25.87 | 2019 | |
| Sunovion Pharmaceuticals INC. | $22.70 | 2022 | |
| Pulmonx Corporation | $22.21 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Amarin Pharma, INC. | $20.22 | 2022 | |
| Antares Pharma, INC. | $20.15 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.41 | 2021 | |
| Sanofi Pasteur INC. | $17.00 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.83 | 2023 | Rexulti |
| Dynavax Technologies Corporation | $16.81 | 2022 | |
| Dexcom, INC. | $14.09 | 2022 | |
| Circassia INC. | $13.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.41 | 2023 | Eliquis |
| Corium, LLC | $12.74 | 2022 | |
| Supernus Pharmaceuticals, INC. | $12.39 | 2019 | |
| Biogen, INC. | $11.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Komer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.